AI assistant
Ventripoint Diagnostics Ltd. — Regulatory Filings 2021
Jan 15, 2021
45675_rns_2021-01-15_c31f1ae5-27df-48d3-a87b-8c06f7aad0cb.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
FO02=15 RM 51-102F3 MATERIAL CHANGE REPORT
1. Name and Address of Company
Ventripoint Diagnostics Ltd. (the " Company ") 2 Sheppard Ave. E. Suite 605
Toronto, ON M2N 5Y7
2. Date of Material Change
January 15, 2021
3. News Release
January 13, 2021. A news release was issued and disseminated through the facilities of a recognized newswire service.
4. Summary of Material Change
The material change is fully described in the Company’s press release which is attached as Schedule “A” and is incorporated herein.
5. Full Description of Material Change
A description of the material change is contained under Item 4.
6.
Reliance on subsection 7.1(2) of National Instrument 51-102
The report is not being filed in reliance on section 7.1(2) of National Instrument 51-102.
7. Omitted Information
No information has been omitted.
8. Executive Officer
The name of the executive officer of the Company who is knowledgeable about the material change and this report is:
Dr. George Adams, Chief Executive Officer Tel: (519) 803-6937 Email: [email protected]
9. Date of Report
January 15, 2020.
SCHEDULE “A”
PRESS RELEASE
Ventripoint Announces Filing of Articles of Amendment
Toronto, Ontario – The Newswire – January 13, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) announces it has filed articles of amendment in accordance with the Canada Business Corporations Act to change the province in which the registered office of the Company is located from Alberta to Ontario. Shareholders of the Company approved the amendment at the annual and special meeting of shareholders held on December 14, 2020.
A copy of the articles of amendment will be posted on the Company’s issuer profile on SEDAR at www.SEDAR.com
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact: Dr. George Adams [email protected] Tel: 519-803-6937
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.